The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors

Viruses

Volumn 6, Issue 8, 2014, Pages 2960-2973

  Sluis Cremer, Nicolas ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Dapivirine; Efavirenz; Etravirine; HIV; MIV 150; Nevirapine; Nonnucleoside inhibitors; Reverse transcriptase; Rilpivirine

Indexed keywords

ABACAVIR; DAPIVIRINE; DELAVIRDINE; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; MICROBICIDE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CROSS RESISTANCE; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVERSE TRANSCRIPTION; REVIEW; VIRUS LOAD; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84905583408     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v6082960     Document Type: Review

References (51)

1. Telesnitsky, A.; Goff, S. Reverse Transcriptase and the Generation of Retroviral DNA in Retroviruses; Coffin, J., Hughes, S., Varmus, H., Eds.; Cold Spring Harbor Laboratory Press: Plainview, NY, USA. 1997; pp. 121-160.
2. Das, K.; Arnold, E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Curr. Opin. Virol. 2013, 3, 111-118.
3. Das, K.; Arnold, E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Curr. Opin. Virol. 2013, 3, 119-128.
4. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3. 5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 26, 1783-1790.
5. Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
6. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D., Jr.; Hughes, S. H.; Arnold, E. Structure of unliganded HIV-1 reverse transcriptase at 2. 7 A resolution: Implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996, 15, 853-860.
7. Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J. C.; Shih, C. K.; Eckner, K.; Hattox, S.; Adams, J. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990, 250, 1411-1413.
8. Havlir, D.; McLaughlin, M. M.; Richman, D. D. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of >500/mm3: AIDS Clinical Trials Group Protocol 208. J. Infect. Dis. 1995, 172, 1379-1383.
9. Richman, D. D.; Havlir, D.; Corbeil, J.; Looney, D.; Ignacio, C.; Spector, S. A.; Sullivan, J.; Cheeseman, S.; Barringer, K.; Pauletti, D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 1994, 68, 1660-1666.
10. Larder, B. A. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 1992, 36, 2664-2669.
11. Selmi, B.; Deval, J.; Alvarez, K.; Boretto, J.; Sarfati, S.; Guerreiro, C.; Canard, B. The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer. J. Biol. Chem. 2003, 278, 40464-40472.
12. Brenner, B.; Turner, D.; Oliveira, M.; Moisi, D.; Detorio, M.; Carobene, M.; Marlink, R. G.; Schapiro, J.; Roger, M.; Wainberg, M. A. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003, 17, F1-F5.
13. Yap, S. H.; Sheen, C. W.; Fahey, J.; Zanin, M.; Tyssen, D.; Lima, V. D.; Wynhoven, B.; Kuiper, M.; Sluis-Cremer, N.; Harrigan, P. R.; et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007, 4, e335.
14. Brehm, J. H.; Koontz, D. L.; Wallis, C. L.; Shutt, K. A.; Sanne, I.; Wood, R.; McIntyre, J. A.; Stevens, W. S.; Sluis-Cremer, N.; Mellors, J. W. CIPRA-SA Project 1 Study Team. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin. Infect. Dis. 2012, 55, 737-745.
15. Ton, Q.; Frenkel, L. HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission. Curr. HIV Res. 2013, 11, 126-136.
16. Young, S. D.; Britcher, S. F.; Tran, L. O.; Payne, L. S.; Lumma, W. C.; Lyle, T. A.; Huff, J. R.; Anderson, P. S.; Olsen, D. B.; Carroll, S. S. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39, 2602-2605.
17. Nelson, M.; Staszewski, S.; Morales-Ramirez, J. O.; Barros, C.; Ferrer, E.; Milazzo, F. Successful virologic suppression with efavirenz in HIV-infected patients with low baseline CD4 cell counts: Post hoc results from study 006. In Proceedings of the Abstracts of the Tenth European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, Sweden, 28-31 May 2000; Abstract 3-349.
18. Squires, K.; Lazzarin, A.; Gatell, J. M.; Powderly, W. G.; Pokrovskiy, V.; Delfraissy, J. F.; Jemsek, J.; Rivero, A.; Rozenbaum, W.; Schrader, S.; et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 2004, 36, 1011-1019.
19. Yeni, P.; Cooper, D. A.; Aboulker, J. P.; Babiker, A. G.; Carey, D.; Darbyshire, J. H.; Floridia, M.; Girard, P. M.; Goodall, R. L.; Hooker, M. H.; et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: Open-label randomised trial. Lancet 2006, 368, 287-298.
20. Van Leth, F.; Phanuphak, P.; Ruxrungtham, K.; Baraldi, E.; Miller, S.; Gazzard, B.; Cahn, P.; Lalloo, U. G.; van der Westhuizen, I. P.; Malan, D. R.; et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004, 363, 1253-1263.
21. Gulick, R. M.; Ribaudo, H. J.; Shikuma, C. M.; Lustgarten, S.; Squires, K. E.; Meyer, W. A., 3rd; Acosta, E. P.; Schackman, B. R.; Pilcher, C. D., Murphy, R. L.; et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 2004, 350, 1850-1861.
22. Cooper; D. A.; Heera; J.; Goodrich; J.; Tawadrous; M.; Saag; M.; Dejesus; E.; Clumeck; N.; Walmsley; S.; Ting; N.; Coakley; E.; et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J. Infect. Dis. 2010, 201, 803-813.
23. Markowitz, M.; Nguyen, B. Y.; Gotuzzo, E.; Mendo, F.; Ratanasuwan, W.; Kovacs, C.; Prada, G.; Morales-Ramirez, J. O.; Crumpacker, C. S.; Isaacs, R. D.; et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 2007, 46, 125-133.
24. Lennox, J. L.; DeJesus, E.; Lazzarin, A.; Pollard, R. B.; Madruga, J. V.; Berger, D. S.; Zhao, J.; Xu, X.; Williams-Diaz, A.; Rodgers, A. J.; et al. STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 2009, 374, 796-806.
25. Lennox, J. L.; Dejesus, E.; Berger, D. S.; Lazzarin, A.; Pollard, R. B.; Ramalho Madruga, J. V.; Zhao, J.; Wan, H.; Gilbert, C. L.; Teppler, H.; et al. STARTMRK Investigators. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acquir. Immune Defic. Syndr. 2010, 55, 39-48.
26. Rockstroh, J. K.; Lennox, J. L.; Dejesus, E.; Saag, M. S.; Lazzarin, A.; Wan, H.; Walker, M. L.; Xu, X.; Zhao, J.; Teppler, H.; et al. STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin. Infect. Dis. 2011, 53, 807-816.
27. Rockstroh, J. K.; DeJesus, E.; Lennox, J. L.; Yazdanpanah, Y.; Saag, M. S.; Wan, H.; Rodgers, A. J.; Walker, M. L.; Miller, M.; DiNubile, M. J.; et al. STARTMRK Investigators. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: Final 5-year results from STARTMRK. J. Acquir. Immune Defic. Syndr. 2013, 63, 77-85.
28. Walmsley, S. L.; Antela, A.; Clumeck, N.; Duiculescu, D.; Eberhard, A.; Gutiérrez, F.; Hocqueloux, L.; Maggiolo, F.; Sandkovsky, U.; Granier, C.; et al. SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N. Engl. J. Med. 2013, 369, 1807-1818.
29. Vingerhoets, J.; Azijn, H.; Fransen, E.; De Baere, I.; Smeulders, L.; Jochmans, D.; Andries, K.; Pauwels, R.; de Béthune, M. P. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J. Virol. 2005, 79, 12773-12782.
30. Madruga, J. V.; Cahn, P.; Grinsztejn, B.; Haubrich, R.; Lalezari, J.; Mills, A.; Pialoux, G.; Wilkin, T.; Peeters, M.; Vingerhoets, J.; et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370, 29-38.
31. Lazzarin, A.; Campbell, T.; Clotet, B.; Johnson, M.; Katlama, C.; Moll, A.; Towner, W.; Trottier, B.; Peeters, M.; Vingerhoets, J.; et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370, 39-48.
32. Tambuyzer, L.; Vingerhoets, J.; Azijn, H.; Daems, B.; Nijs, S.; de Béthune, M. P.; Picchio, G. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res. Hum. Retroviruses 2010, 26, 1197-1205.
33. Vingerhoets, J.; Tambuyzer, L.; Azijn, H.; Hoogstoel, A.; Nijs, S.; Peeters, M.; de Béthune, M. P.; De Smedt, G.; Woodfall, B.; Picchio, G. Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010, 24, 503-514.
34. Ruxrungtham, K.; Pedro, R. J.; Latiff, G. H.; Conradie, F.; Domingo, P.; Lupo, S.; Pumpradit, W.; Vingerhoets, J. H.; Peeters, M.; Peeters, I.; et al. TMC125-C227 study group. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: Study TMC125-C227. HIV Med. 2008, 9, 883-896.
35. Azijn, H.; Tirry, I.; Vingerhoets, J.; de Béthune, M. P.; Kraus, G.; Boven, K.; Jochmans, D.; Van Craenenbroeck, E.; Picchio, G.; Rimsky, L. T. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents Chemother. 2010, 54, 718-727.
36. Molina, J. M.; Cahn, P.; Grinsztejn, B.; Lazzarin, A.; Mills, A.; Saag, M.; Supparatpinyo, K.; Walmsley, S.; Crauwels, H.; Rimsky, L. T.; et al. ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet 2011, 378, 238-246.
37. Cohen, C. J.; Andrade-Villanueva, J.; Clotet, B.; Fourie, J.; Johnson, M. A.; Ruxrungtham, K.; Wu, H.; Zorrilla, C.; Crauwels, H.; Rimsky, L. T.; et al. THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): A Phase 3, randomized, non-inferiority trial. Lancet 2011, 378, 229-237.
38. Xu, H. T.; Asahchop, E. L.; Oliveira, M.; Quashie, P. K.; Quan, Y.; Brenner, B. G.; Wainberg, M. A. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J. Virol. 2011, 85, 11300-11308.
39. Hu, Z.; Kuritzkes, D. R. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: Effects on fitness and RT activity of human immunodeficiency virus type 1. J. Virol. 2011, 85, 11309-11314.
40. Kulkarni, R.; Babaoglu, K.; Lansdon, E. B.; Rimsky, L.; van Eygen, V.; Picchio, G.; Svarovskaia, E.; Miller, M. D.; White, K. L. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J. Acquir. Immune Defic. Syndr. 2012, 59, 47-54.
41. Sluis-Cremer, N.; Jordan, M. R.; Huber, K.; Wallis, C. L.; Bertagnolio, S.; Mellors, J. W.; Parkin, N. T.; Harrigan, P. R. E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings. Antivir. Res. 2014, 107, 31-34.
42. Siegel, M. O.; Swierzbinski, M.; Kan, V. L.; Parenti, D. M. Baseline E138 reverse transcriptase resistance-associated mutations in antiretroviral-naive HIV-infected patients. AIDS 2012, 26, 1181-1182.
43. Baert, L.; van't Klooster, G.; Dries, W.; François, M.; Wouters, A.; Basstanie, E.; Iterbeke, K.; Stappers, F.; Stevens, P.; Schueller, L.; et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 2009, 72, 502-508.
44. Van't Klooster, G.; Hoeben, E.; Borghys, H.; Looszova, A.; Bouche, M. P.; van Velsen, F.; Baert, L. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 2010, 54, 2042-2050.
45. Verloes, R.; van't Klooster, G.; Baert, L.; van Velsen, F.; Bouche, M. P.; Spittaels, K.; Leempoels, J.; Williams, P.; Kraus, G.; Wigerinck, P. TMC278 Long Acting-A Parenteral Nanosuspension Formulation that Provides Sustained Clinically Relevant Plasma Concentrations in HIV-Negative Volunteers. In Proceedings of the 17th International AIDS Conference, Mexico City, Mexico, 23 November 2008.
46. Jackson, A.; Else, L.; Tjia, J.; Seymour, N.; Stafford, M.; Back, D.; Gazzard, B.; Boffito, M. Rilpivirine-LA Formulation: Pharmacokinetics in Plasma, Genital Tract in HIV-Females and Rectum in Males [Abstract no. 35]. In Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 5-8 March 2012.
47. Fletcher, P.; Harman, S.; Azijn, H.; Armanasco, N.; Manlow, P.; Perumal, D.; de Bethune, M. P.; Nuttall, J.; Romano, J.; Shattock, R. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 2009, 53, 487-495.
48. Schader, S. M.; Oliveira, M.; Ibanescu, R. I.; Moisi, D.; Colby-Germinario, S. P.; Wainberg, M. A. In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrob. Agents Chemother. 2012, 56, 751-756.
49. Kenney, J.; Aravantinou, M.; Singer, R.; Hsu, M.; Rodriguez, A.; Kizima, L.; Abraham, C. J.; Menon, R.; Seidor, S.; Chudolij, A.; et al. An Antiretroviral/Zinc combination gel provides 24 h of complete protection against vaginal SHIV infection in macaques. PLoS One 2011, 6, e15835.
50. Singer, R.; Mawson, P.; Derby, N.; Rodriguez, A.; Kizima, L.; Menon, R.; Goldman, D.; Kenney, J.; Aravantinou, M.; Seidor, S.; et al. An Intravaginal Ring That Releases the NNRTI MIV-150 Reduces SHIV Transmission in Macaques. Sci. Transl. Med. 2012, 4, 150ra123.
51. Hsu, M.; Keele, B. F.; Aravantinou, M.; Krawczyk, N.; Seidor, S.; Abraham, C. J.; Zhang, S.; Rodriguez, A.; Kizima, L.; Derby, N.; et al. Exposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaques. PLoS One 2014, 9, e89300.